S.BIOMEDICS has reported encouraging one-year post-transplant outcomes from a Phase I/IIa study of its cell therapy, TED-A9, for treating Parkinson's disease. The data revealed improvements in both ...
SEOUL, South Korea--(BUSINESS WIRE)--S.BIOMEDICS Co., Ltd. (KOSDAQ: 304360) announced that it has successfully completed the brain transplant of TED-A9 (hESC-derived dopaminergic progenitors) for ...
TED-A9 is an allogeneic cell therapy in development for Parkinson’s disease Program builds on S.Biomedics’ growing pipeline of stem-cell-based therapies Catalent and S.Biomedics today announced a ...
KOSDAQ-listed S.Biomedics was strong early on the 14th. Buying is seen as flocking to the stock on news that Phase 1 clinical results in patients with Parkinson's disease were published in the leading ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
TAMPA, Fla. & SEOUL, South Korea, February 18, 2026--(BUSINESS WIRE)--Catalent and S.Biomedics today announced a strategic partnership to support the development and manufacturing of TED‑A9, ...
Explore the KQ:304360 financials. Find the S Biomedics financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results